The future of infectious disease diagnostics

Discover - rapid syndromic testing

Get the right diagnosis the first time

Patients with infectious illnesses often have signs and symptoms that are indicative of a disease, but that aren't specific enough to clinically distinguish what makes them ill. These patients are frequently given broad treatment, heavy monitoring and possibly unnecessary interventions. This puts a burden on healthcare systems, clinical labs and clinicians, and means patients aren't getting the best care possible.

We’re committed to helping healthcare workers like you navigate the challenges of diagnosing infectious diseases. That’s why we’ve developed an easy-to-use, automated diagnostic testing system that can help eliminate the guesswork and make your job easier. Our tests use multiplex PCR technology – also known as syndromic testing – that can quickly survey many different pathogens in a single patient sample. With syndromic testing, you get the answers you need, when you need them. And your patients get better care, faster.

Latest insights
–
webinars, stories and more

Syndromic testing webinar hub
Watch our most recent webinars to learn how experts have incorporated syndromic testing into their diagnostic approach. Plus, get the latest insights on molecular diagnostics for infectious diseases.
LEARN MORE
New rapid test for meningitis/encephalitis
Rapid diagnosis of central nervous system infections is crucial for successful patient outcomes. That's why we've introduced a new syndromic panel that can differentiate 15 pathogens in around 1 hour.
Learn more
Take your diagnostics to new heights
Meet the QIAstat-Dx Rise (coming soon), the newest member of the QIAstat-Dx family. The QIAstat-Dx Rise lifts multiplex syndromic testing to new heights, combining a quick and easy workflow with increased testing capacity.
Learn more
Adopting a new approach to serve the community during COVID-19
When COVID-19 struck in Indiana, USA, CEO and president of Great Lakes Labs, Michelle Volk, knew that she wanted to help. Learn how she adopted syndromic testing to help provide fast answers and peace of mind to her community.
READ HER STORY
Can your testing platform talk to you?
The QIAstat-Dx Analyzer can, with push notifications sent through the QIAsphere app. The app works in harmony with your local network to help you maximize productivity – learn more in our connectivity guide.
GET THE GUIDE

male person reading an ebook in front of a window

Meet the challenges this respiratory season will bring

The arrival of the influenza-like illness season has coincided with another rise in COVID-19 cases, as the pandemic continues across the globe. Syndromic testing can simplify the diagnosis of respiratory diseases and help facilitate fast clinical decision making.

This respiratory season will be uniquely challenging

Visit our respiratory resources hub to learn how we can support you.

VIEW RESOURCES

Voices from the field
–
how medical professionals are using syndromic diagnostics

“It changed our perception, our prescription habits, and it will change the way we work in the future. In the end, we gain money for both the community and the patients. That is really a big step forward.”

Celestin Alexis Agbessi, M.D., Bichat-Claude Bernard Hospital, Paris

“It’s hugely beneficial to be able to test for that wide range of pathogens. Ruling out COVID is helpful, but so is the chance to correctly identify other illnesses so physicians can treat the patients and their symptoms appropriately.”

Michelle Volk, CEO and president of Great Lakes Labs, Indiana, USA

“Our value to our patients and to our provider community has increased by bringing the QIAstat-Dx in-house.”

Joshua Arant, Founder and Chief Operations Officer, Mako Medical

Why choose syndromic testing as a diagnostic tool?

Laboratory benefits
- Easy to set up a test, with less than one minute hands-on time
- Increased analytical sensitivity^1,2,3 versus traditional methods
- Ct data and amplification curves visible for detected pathogens
Patient benefits
- Comprehensive results for more than 20 pathogens with faster turnaround times⁴ can support faster clinical decision making
- Associated with reduced hospital length of stay⁵, improved patient management⁶ and better outcomes⁷
Antimicrobial stewardship benefits
- Comprehensive results allow causative pathogens to be identified quickly
- Supports the use of a targeted therapeutic approach to reduce inappropriate antibiotic use⁸ and antibiotic duration⁸
Healthcare cost benefits
- A reduction in the need for follow-up testing, shorter hospital stays and more efficient testing can reduce overall healthcare costs⁹

New to rapid diagnostics with syndromic testing?

Find the information you need and learn how to incorporate syndromic testing into your diagnostic strategy.

LEARN MORE

Featured
–
resources for infectious disease diagnostics

A simple syndromic workflow
See how quick and intuitive syndromic testing can be. Use this interactive demo to try out the QIAstat-Dx Analyzer for yourself.
TRY AN INTERACTIVE DEMO
Top 3 considerations during respiratory season
As we enter respiratory season, one topic drawing attention is co-infections between influenza-like illnesses and COVID-19.
Read the article
COVID-19 solutions and resources
Learn more about how QIAGEN solutions can be used in the fight against COVID-19, or get in touch to let us know how we can support your lab.
FIND SOLUTIONS

icon-cta-contact

Have a question about multiplex panel testing?

Get in touch with us today.

Contact us

References

Yalamanchili H, et al. (2018) Gastroenterol Hepatol, 14(11):646-652
Binnicker M. Multiplex. (2015) J. Clin Microbiology, 53(12):3723-3728
Macfarlane-Smith L, et al. (2018) Gastrointestinal Infections, 34(1):19-2
Echavarria M, et al. (2018) J Clin Virol, 108:90–95
Beal S G, et al. (2018) J Clin Microbiol, 18;56(1)
Bouzid D, et al. (2020) J Hospital Infection, 337-338
Iroh Tam PY, et al. (2017) Children (Basel), 4(1)
Zhu et al. (2018) Clin Pediatr, 58(2): 185-190
Martinez RM, et al. (2016) Clinical Virology Symposium, Poster #C-368

The QIAstat-Dx Analyzer, QIAstat-Dx Respiratory SARS-CoV-2 Panel and QIAstat-Dx Gastrointestinal Panel are intended for in vitro diagnostic use.

The QIAstat-Dx ME Panel is indicated as an aid in the diagnosis of specific agents that cause meningitis and/or encephalitis, and results must be used in conjunction with other clinical, epidemiological, and laboratory data. Results from the QIAstat-Dx ME Panel are not intended to be used as the sole basis for diagnosis, treatment, or other patient management decisions. Positive results do not rule out co-infection with organisms not included in the QIAstat-Dx ME Panel. The agent or agents detected may not be the definite cause of the disease. Negative results do not preclude central nervous system (CNS) infection.

The QIAstat-Dx ME Panel is intended for in vitro diagnostic use by laboratory professionals only.

Product availability may differ from country to country based on regulations and approvals. Contact your country representative for further details.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user manual.